Instrument Inactif

Gouvernance Audentes Therapeutics, Inc.

US05070R1041

Recherche biotechnologique et médicale

Comité Exécutif: Audentes Therapeutics, Inc.

Dirigeant

Fonctions occupéesDepuis

Jason Schwartz

Chief Tech/Sci/R&D Officer

01/06/2022

David Smethurst

General Counsel

01/08/2021

Morten Sogaard

Chief Tech/Sci/R&D Officer	-
President	-

Composition du Conseil d'Administration: Audentes Therapeutics, Inc.

Administrateur

ComitésDepuis

Kush Parmar

45 ans

Compensation Committee Chair	05/12/2023
Governance Committee Chair
Nominating Committee Chair

Alan Beggs

Director/Board Member

Anciens Dirigeants et Administrateurs: Audentes Therapeutics, Inc.

Insider

Fonctions occupées

DepuisJusqu'au

Chris Lorenz

Chief Tech/Sci/R&D Officer

01/10/2022

Edward Conner

Chief Tech/Sci/R&D Officer	15/05/2019	-
Corporate Officer/Principal	-	01/07/2021

Sarah Spencer

Public Communications Contact

01/04/2019

01/04/2021

Natalie Holles

Director/Board Member	15/01/2020	01/03/2021
Chief Executive Officer	15/01/2020	01/03/2021
Chief Operating Officer	01/08/2015	15/01/2020
President	08/05/2018	01/03/2021

Jason O’Byrne

Director of Finance/CFO

01/04/2019

01/02/2021

Julie Person

Human Resources Officer

01/04/2020

01/01/2021

Eric Mosbrooker

Corporate Officer/Principal

03/01/2019

01/01/2021

Donald Wuchterl

Corporate Officer/Principal

01/01/2016

01/01/2021

Thomas Soloway

Comptroller/Controller/Auditor	29/09/2015	15/01/2020
Chief Operating Officer	-	01/09/2020
Director of Finance/CFO	29/09/2015	01/09/2020
Treasurer	15/01/2020	01/09/2020

Catherine Parham

Chief Tech/Sci/R&D Officer

01/08/2020

Tracy Porter

Human Resources Officer

01/03/2019

01/03/2020

Mark Meltz

General Counsel

28/03/2019

01/02/2020

Thomas Schuetz

Director/Board Member	01/07/2013	15/01/2020
Founder	13/11/2012	15/01/2020
Independent Dir/Board Member	01/07/2013	15/01/2020

Julie Smith

Director/Board Member	13/12/2016	15/01/2020
Independent Dir/Board Member	13/12/2016	15/01/2020

Jennifer Jarrett

Director/Board Member	13/06/2017	15/01/2020
Independent Dir/Board Member	13/06/2017	15/01/2020

Scott Morrison

Director/Board Member	01/12/2015	15/01/2020
Independent Dir/Board Member	01/12/2015	15/01/2020

Masaaki Hirano

Director/Board Member

15/01/2020

Toru Yoshimitsu

Director/Board Member

15/01/2020

Louis Lange

Director/Board Member	01/08/2015	15/01/2020
Independent Dir/Board Member	01/08/2015	15/01/2020

Matt Patterson

Director/Board Member	13/11/2012	05/11/2018
Chief Executive Officer	13/11/2012	15/01/2020
Chairman	05/11/2018	15/01/2020
Founder	13/11/2012	15/01/2020
President	13/11/2012	08/05/2018

Percival Barretto-Ko

Director/Board Member

15/01/2020

Mark Goldberg

Director/Board Member	13/12/2017	15/01/2020
Independent Dir/Board Member	13/12/2017	15/01/2020

Andrew H. Chang

Investor Relations Contact

01/01/2020

Suyash Prasad

Chief Tech/Sci/R&D Officer

01/02/2014

30/06/2019

John T. Gray

Chief Tech/Sci/R&D Officer

01/07/2014

31/05/2019

David Nagler

Human Resources Officer

01/04/2013

01/07/2018

Stephen Squinto

Director/Board Member	21/04/2015	01/01/2018
Independent Dir/Board Member	21/04/2015	01/01/2018

Jonathan Silverstein

Chairman	01/12/2012	12/07/2017
Independent Dir/Board Member	01/12/2012	12/07/2017

Thomas Woiwode

Director/Board Member	01/07/2013	12/07/2017
Independent Dir/Board Member	01/07/2013	12/07/2017

Jason Barker

Director of Finance/CFO

01/02/2015

29/09/2015

Kevin P. Baker

Corporate Officer/Principal

29/09/2015

Jonathan Leff

Director/Board Member	01/11/2014	-
Independent Dir/Board Member	01/11/2014	-

Dawn Blessing

Corporate Officer/Principal

01/10/2014

Mary Newman

General Counsel

01/10/2014

Monica Miller

Corporate Officer/Principal

01/12/2013

Barbara Wuebbels

Corporate Officer/Principal

01/10/2013

Katie Hogan

Public Communications Contact

James Healy

Director/Board Member

Rocio Hoyos

Sales & Marketing

Paul Laland

Public Communications Contact

Graeme Fielder

Corporate Officer/Principal

Andrew Krivoshik

President

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	6
Femme	1

Dont comité exécutif

Homme	3
Femme	0

Dont Administrateurs

Homme	2
Femme	0

Audentes Therapeutics, Inc. est une société de biotechnologie en phase de démarrage. La société se concentre sur le développement et la commercialisation de produits de thérapie génique pour les patients souffrant de maladies rares graves et potentiellement mortelles causées par des défauts monogéniques. La société possède un portefeuille de produits candidats, dont l'AT132 pour le traitement de la myopathie myotubulaire liée à l'X (XLMTM) ; l'AT342 pour le traitement du syndrome de Crigler-Najjar (Crigler-Najjar) ; l'AT982 pour le traitement de la maladie de Pompe et l'AT307 pour le traitement du sous-type CASQ2 de la tachycardie ventriculaire polymorphe catécholaminergique (CASQ2-CPVT). La filiale de la société est Audentes Therapeutics UK Ltd. Au 30 septembre 2016, la Société n'avait pas généré de revenus.

Employés

Secteur

Recherche biotechnologique et médicale

Plus d'informations sur la société